Amgen joins M&A rush with deals for Dezima and Xencor
September 16, 2015Research and Development, Sales and Marketing Amgen, Cancer, Denzime, Xencor, cardiovascular disease, high cholesterol, inflammation
Amgen has struck deals that could potentially be worth $3.25 billion, to purchase the Dutch firm Dezima and kick-off a …
NICE rejects Farydak for multiple myeloma
September 16, 2015Sales and Marketing Farydak, NICE, Novartis, multiple myeloma, panobinostat
NICE has rejected Novartis Farydak in its draft guidance, ruling it out as a treatment for multiple myeloma. Farydak (panobinostat) is …
Cancers diagnosed earlier in England, but cases rise
September 16, 2015Cancer, Jeremy Hunt, Public Health England, cancer diagnosis, public health
The proportion of cancers diagnosed by GPs under the ‘two-week wait’ referral pathway rose, and late diagnoses fell, after the …
President Obama nominates Dr Robert Califf as new FDA head
September 16, 2015Manufacturing and Production, Medical Communications
US President Barack Obama has put forward Dr Robert Califf as the next commissioner of the FDA, according to a …
Sanofi’s LixiLan meets target in Phase III diabetes trial
September 16, 2015Research and Development Lantus, LixiLan, Lixisenatide, Lxyumia, Sanofi, diabetes, insulin glargine, metformin, type 2 diabetes
Sanofi’s Phase III clinical trial of its Lixilan treatment has achieved its primary endpoint in patients with type 2 diabetes, …
The biggest side-effect of making medicine
September 16, 2015Research and Development evergreening, intellectual property, patent
International intellectual property regulations are doing serious damage to the pharmaceutical industry and, by extension, to the health of people …
R&D firms team up to tackle antibiotic resistance
September 16, 2015Research and Development AMR, Antibiotics, Jim O'Neill, O'Neill review, antimicrobial resistance, drug development
Two companies at the centre of the UK’s R&D efforts to tackle the growing threat of resistance to antibiotics are expanding …
AstraZeneca scores positive real-world Forxiga data
September 16, 2015Research and Development AstraZeneca, EASD, European Association for the Study of Diabetes, Forxiga, dapagliflozin, exenatide, real world data, real world evidence
The real-world study of AstraZeneca’s diabetes drug Forxiga has found its use in UK patients primary care patients supports the …
GSK recalls 427,000 antibiotics after contamination scare
September 15, 2015Manufacturing and Production Bactroban, FDA, GSK, manufacturing, product recalls, production, recalls
GlaxoSmithKline has had to recall more than 427,000 tubes of creams and ointments due to potential penicillin cross-contamination and the …
Sanofi to significantly expand UK inhaler plant
September 15, 2015Manufacturing and Production Cheshire, Sanofi, manufacturing, production
Sanofi is gearing up for significant expansion of its inhaler production complex in Cheshire, England. The French pharma giant has …
AstraZeneca purchases former Amgen US facility
September 15, 2015Manufacturing and Production Amgen, AstraZeneca, US, biologics, manufacturing, production
AstraZeneca has bolstered its US presence with the purchase of a high-tech biologics manufacturing facility from pharma rival Amgen. The …
PureTech appoints Michael MacLean as chief financial officer
September 14, 2015Medical Communications, Research and Development, Sales and Marketing Michael MacLean, PureTech Health
PureTech Health has appointed Michael MacLean to the management team, as chief financial officer and executive vice president. Michael MacLean …
Counting the true cost of the Cancer Drugs Fund cuts
September 14, 2015Research and Development Cancer, Cancer Drugs Fund, NHS, clinical trials, cuts, oncology
Leading figures from the pharma industry and cancer charities reacted with dismay to the recent cuts to the Cancer Drugs …
FDA strengthens safety warning for J&J’s diabetes drug Invokana
September 14, 2015Sales and Marketing FDA, Food and Drugs Administration, Invokamet, J&J, JJ, Johnson & Johnson, diabetes, invokana, safety warning, type 2 diabetes
Johnson & Johnson has suffered a blow after the FDA strengthened its safety warning for the company’s type 2 diabetes …
Janssen submits EMA application for myeloma drug
September 14, 2015Sales and Marketing Janssen, daratumumab, multiple myeloma
Janssen has submitted a new marketing authorisation application for European approval of daratumumab for the treatment of patients with relapsed …
Boehringer earns NICE nod for IPF drug Ofev
September 14, 2015Sales and Marketing Boehringer Ingelheim, IPF, NICE, idiopathic pulmonary fibrosis
NICE has recommended Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis after the German firm agreed to a …
The making of a modern pharma blockbuster
September 11, 2015Medical Communications Big Pharma, Twice Circled, computer game
The pharma industry divides opinions on its morality, but what has always stood out is the fact that in this …
US FDA accepts first digital medicine application
September 11, 2015Medical Communications FDA, NDA, Otsuka, digital, digital medicine, proteus
The FDA has accepted the first New Drug Application for a digital medicine: Otsuka and Proteus Digital Health’s collaboration of …
Supply chain leaders call for forward pharma thinking
September 11, 2015Manufacturing and Production, Medical Communications fly pharma, fly pharma conference, logistics, supply chain
Logistics companies must improve their understanding of the pharma industry to better serve their customers, according to a supply chain …
Envision Pharma acquires two medical education specialists in takeover deal
September 11, 2015Medical Communications
Two principals from Alligent Biopharm Consulting have joined the UK communications group Envision Pharma following an acquisition deal.Alligent’s two principals, …
Latest content
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
